» Articles » PMID: 8863000

Review: Treatment of Schizophrenia. State of the Art

Overview
Specialties Neurology
Psychiatry
Date 1996 Jan 1
PMID 8863000
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

As a result of the multifactorial etiopathology of schizophrenia, a treatment strategy combining drug therapy with psychosocial measures is indicated. Depending on the stage of the disease and on the individual condition of the patient, the accent is set alternatively more on one approach or on the other. However, under aspects of symptom reduction and relapse prophylaxis, the therapy with neuroleptics plays the most important role. In order to keep their side effects to a minimum during acute and long term treatment, there is nowadays a trend towards administration of the lowest possible dose. Under this aspect, the use of so called atypical neuroleptics should be taken into consideration. The treatment of negative symptoms, especially in the context of chronic residual syndrome, is still a problem which hasn't been solved to satisfaction. Beside the use of atypical neuroleptics, treatment with antidepressives should be tried. During the long term relapse prophylactic treatment, it is important that not only the criterion "reduction of the relapse rate" but also that of individual risk/benefit relation be considered. Concerning psychosocial therapies, especially focused behavioural therapy approaches, for example educational programs and specific family therapeutical intervention following the high-EE-concept, as well as training of social and cognitive competences have proved useful beside supportive psychotherapy and the whole range of sociotherapeutical measures. However they need further evaluation before they get integrated in routine treatment.

Citing Articles

Carbamazepine for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath J Cochrane Database Syst Rev. 2014; (5):CD001258.

PMID: 24789267 PMC: 7032545. DOI: 10.1002/14651858.CD001258.pub3.


[Atypical antipsychotics in therapy refractory schizophrenia].

Schafer I, Lambert M, Naber D Nervenarzt. 2004; 75(1):79-91.

PMID: 14997870 DOI: 10.1007/s00115-003-1662-7.


Enhancement of executive functioning skills: an additional tier in the treatment of schizophrenia.

Davalos D, Green M, Rial D Community Ment Health J. 2002; 38(5):403-12.

PMID: 12236410 DOI: 10.1023/a:1019860428856.

References
1.
RIFKIN A, Doddi S, Karajgi B, Borenstein M, WACHSPRESS M . Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 1991; 48(2):166-70. DOI: 10.1001/archpsyc.1991.01810260074011. View

2.
Baldessarini R, Cohen B, Teicher M . Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988; 45(1):79-91. DOI: 10.1001/archpsyc.1988.01800250095013. View

3.
Reardon G, RIFKIN A, Schwartz A, MYERSON A, Siris S . Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 1989; 146(6):726-9. DOI: 10.1176/ajp.146.6.726. View

4.
Goodnick P, Meltzer H . Treatment of schizoaffective disorders. Schizophr Bull. 1984; 10(1):30-48. DOI: 10.1093/schbul/10.1.30. View

5.
Kane J, HONIGFELD G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-96. DOI: 10.1001/archpsyc.1988.01800330013001. View